
Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
6 Web-based Course Stages for Successful Learning and Educating - 2
Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts - 3
Step by step instructions to Guarantee the Life span of Your Dental Inserts: Support and Care Guide - 4
Want to read more in 2026? Here's how to revive your love of books - 5
James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
Former Israeli judge does not expect Netanyahu to be pardoned
Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
Pick Your Favored kind of salad
6 Exemplary Mexican Dishes
Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
How the Iran war may affect your money and bills
An Investigate of 6 Creative Specialty Mixed drinks
Whale stranded off Germany for days found stuck again
Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond













